Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161

Angela M. Lam,Ravi R. Dugyala,Muhammed Sheraz,Fei Liu,Emily P. Thi,Ingrid E. Graves,Andrea Cuconati,Holly Micolochick Steuer,Andrzej Ardzinski,Nathan Overholt,Jeremy D. Mason,Dimitar Gotchev,Andrew G. Cole,Troy O. Harasym,Michael J. Sofia

DOI: https://doi.org/10.3390/v16030323

2024-02-22

Viruses

Abstract:HBV RNA destabilizers are a class of small-molecule compounds that target the noncanonical poly(A) RNA polymerases PAPD5 and PAPD7, resulting in HBV RNA degradation and the suppression of viral proteins including the hepatitis B surface antigen (HBsAg). AB-161 is a next-generation HBV RNA destabilizer with potent antiviral activity, inhibiting HBsAg expressed from cccDNA and integrated HBV DNA in HBV cell-based models. AB-161 exhibits broad HBV genotype coverage, maintains activity against variants resistant to nucleoside analogs, and shows additive effects on HBV replication when combined with other classes of HBV inhibitors. In AAV-HBV-transduced mice, the dose-dependent reduction of HBsAg correlated with concentrations of AB-161 in the liver reaching above its effective concentration mediating 90% inhibition (EC90), compared to concentrations in plasma which were substantially below its EC90, indicating that high liver exposure drives antiviral activities. In preclinical 13-week safety studies, minor non-adverse delays in sensory nerve conductance velocity were noted in the high-dose groups in rats and dogs. However, all nerve conduction metrics remained within physiologically normal ranges, with no neurobehavioral or histopathological findings. Despite the improved neurotoxicity profile, microscopic findings associated with male reproductive toxicity were detected in dogs, which subsequently led to the discontinuation of AB-161's clinical development.

virology

What problem does this paper attempt to address?

This paper aims to address the issues present in the treatment of chronic hepatitis B virus (HBV) infection. Specifically, currently approved treatments, such as pegylated interferon-alpha (PEG-IFN α) and nucleos(t)ide analogs (NA), have limited effectiveness in achieving functional cure, defined as sustained suppression of HBV DNA and loss of hepatitis B surface antigen (HBsAg). Additionally, PEG-IFN α has adverse side effects, while long-term use of NA is typically required to suppress viral replication. Despite this, data indicate that HBV viremia persists even under stable NA treatment, potentially putting the host at risk for liver-related diseases.

To address these issues, the research team developed a novel HBV RNA degrader, AB-161, a small molecule compound that promotes the degradation of viral transcripts by targeting atypical polyadenylate RNA polymerase-associated proteins PAPD5 and PAPD7. Unlike existing direct-acting antiviral drugs, AB-161 inhibits the production of viral proteins, including HBsAg, by degrading HBV RNA. In various HBV cell models, AB-161 demonstrated potent antiviral activity, broad coverage of HBV genotypes, and effectiveness against resistant variants.

However, in a 13-week toxicology study, while neurotoxicity was improved, adverse findings related to male reproductive toxicity were observed in dogs, ultimately leading to the discontinuation of AB-161's clinical development. Therefore, the focus of this paper is to evaluate the antiviral properties and safety of AB-161 in the hope of finding a more effective HBV treatment.